# Long-Acting Injectables for the Treatment of HIV in Non-Clinic Community-Based Settings

Source: https://welltoldgrants.com/grants/rfa-ps-23-004-long-acting-injectables-for-the-treatment-of-hiv/  
Official notice: https://www.grants.gov/search-results-detail/343380

> Centers for Disease Control and Prevention - ERA offered grants of up to $1.0 million (at least $750,000) to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make one award worth $4.0 million in total. Applications closed on February 27, 2023.

| Field | Value |
|---|---|
| Opportunity number | RFA-PS-23-004 |
| Agency | Centers for Disease Control and Prevention - ERA |
| Status | Forecast |
| Deadline | February 27, 2023 |
| Award ceiling | $1.0 million |
| Award floor | $750,000 |
| Expected awards | 1 |
| Total funding | $4.0 million |
| Cost sharing | not required |
| Assistance Listings | 93.084 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses

N/A

## What the grant funds

The purpose of this notice of funding opportunity is to support research on Long-Acting Injectable-Antiretroviral Therapy (LAI-ART) by implementing LAI-ART administration in both clinic and non-clinic settings (e.g., community pharmacies). A multi-site effectiveness-implementation research study designed to compare receiving LAI-ART in clinic or pharmacy settings with the oral standard-of-care for the treatment of HIV will offer a unique source of information for improving acceptability, availability, and uptake of LAI-ART. Implementation outcomes of interest include acceptability, perceived barriers and facilitators, feasibility, and sustainability. Health outcomes of interest include missed visits, on-time receipt of injections, and the HIV care continuum, including retention in care and viral load suppression. The data collected will describe real-world LAI-ART use among persons with HIV (PWH) in an era of multiple HIV treatment modalities. Applied qualitative and quantitative research resulting from this funding is expected to strengthen adherence to ART.

## Questions people ask

### Is RFA-PS-23-004 still open?

No. It closed on February 27, 2023. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.

### Who can apply for Long-Acting Injectables for the Treatment of HIV in Non-Clinic Community-Based Settings?

Centers for Disease Control and Prevention - ERA accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Long-Acting Injectables for the Treatment of HIV in Non-Clinic Community-Based Settings?

Closed February 27, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $1.0 million each. About $4.0 million in total for one award.

### Who has won Prevention of Disease, Disability, and Death by Infectious Diseases   grants before?

The largest recipients over five fiscal years were Puerto Rico Science, Technology, and Research Trust, Massachusetts Department of Public Health, Emory University. The program made 128 awards worth $241 million in that time.